GEN Exclusives

More »

GEN News Highlights

More »
Aug 25, 2009

BioAlliance Gets Swiss Regulatory Okay for Oral Candidasis Drug

  • BioAlliance Pharma’s share price opened today 8.5% up on the announcement that the Swiss regulatory authorities had sanctioned Loramyc®, its mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients.

    Swiss approval comes less than a week after FDA confirmed its acceptance of the NDA submission for the drug. If sanction in the U.S., Loramyc will be marketed in the country by Strativa Pharmaceuticals.

    Loramyc was first given the go-ahead in France in 2007, and roll-out in additional European countries continues. The drug made sales of €1 million, or roughly $1.43 million, in 2008. In February 2009 BioAlliance terminated its licensing agreement with SpeBio (a joint venture with SpePharm), originally signed in 2007, covering the distribution of Loramyc in EU countries excluding France. BioAlliance also initiated legal proceedings against SpeBio, citing the latter’s violation of its contractual obligations. 

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?